768 related articles for article (PubMed ID: 18199548)
1. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
[TBL] [Abstract][Full Text] [Related]
2. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma.
Ebos JM; Bocci G; Man S; Thorpe PE; Hicklin DJ; Zhou D; Jia X; Kerbel RS
Mol Cancer Res; 2004 Jun; 2(6):315-26. PubMed ID: 15235107
[TBL] [Abstract][Full Text] [Related]
3. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
[TBL] [Abstract][Full Text] [Related]
4. Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis.
Zeng Y; Opeskin K; Goad J; Williams ED
Cancer Res; 2006 Oct; 66(19):9566-75. PubMed ID: 17018613
[TBL] [Abstract][Full Text] [Related]
5. Expression of soluble vascular endothelial growth factor receptor-1 in human monocyte-derived mature dendritic cells contributes to their antiangiogenic property.
Kishuku M; Nishioka Y; Abe S; Kishi J; Ogino H; Aono Y; Azuma M; Kinoshita K; Batmunkh R; Makino H; Ranjan P; Minakuchi K; Sone S
J Immunol; 2009 Dec; 183(12):8176-85. PubMed ID: 20007583
[TBL] [Abstract][Full Text] [Related]
6. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia.
Wierzbowska A; Robak T; Wrzesień-Kuś A; Krawczyńska A; Lech-Marańda E; Urbańska-Ryś H
Eur Cytokine Netw; 2003; 14(3):149-53. PubMed ID: 14656688
[TBL] [Abstract][Full Text] [Related]
7. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.
Bocci G; Man S; Green SK; Francia G; Ebos JM; du Manoir JM; Weinerman A; Emmenegger U; Ma L; Thorpe P; Davidoff A; Huber J; Hicklin DJ; Kerbel RS
Cancer Res; 2004 Sep; 64(18):6616-25. PubMed ID: 15374976
[TBL] [Abstract][Full Text] [Related]
8. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer.
Shin VY; Wu WK; Chu KM; Wong HP; Lam EK; Tai EK; Koo MW; Cho CH
Mol Cancer Res; 2005 Nov; 3(11):607-15. PubMed ID: 16317086
[TBL] [Abstract][Full Text] [Related]
9. Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice.
Brantley-Sieders DM; Fang WB; Hwang Y; Hicks D; Chen J
Cancer Res; 2006 Nov; 66(21):10315-24. PubMed ID: 17079451
[TBL] [Abstract][Full Text] [Related]
10. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis.
Shirakami Y; Shimizu M; Adachi S; Sakai H; Nakagawa T; Yasuda Y; Tsurumi H; Hara Y; Moriwaki H
Cancer Sci; 2009 Oct; 100(10):1957-62. PubMed ID: 19558547
[TBL] [Abstract][Full Text] [Related]
11. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803.
Tian X; Song S; Wu J; Meng L; Dong Z; Shou C
Biochem Biophys Res Commun; 2001 Aug; 286(3):505-12. PubMed ID: 11511087
[TBL] [Abstract][Full Text] [Related]
14. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
LaMontagne KR; Butler J; Borowski VB; Fuentes-Pesquera AR; Blevitt JM; Huang S; Li R; Connolly PJ; Greenberger LM
Angiogenesis; 2009; 12(3):287-96. PubMed ID: 19544081
[TBL] [Abstract][Full Text] [Related]
15. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
Pan JP; Weng YS; Wu QQ
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
[TBL] [Abstract][Full Text] [Related]
16. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
Holloway SE; Beck AW; Shivakumar L; Shih J; Fleming JB; Brekken RA
Ann Surg Oncol; 2006 Aug; 13(8):1145-55. PubMed ID: 16791450
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
[TBL] [Abstract][Full Text] [Related]
18. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development.
Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H
Oncol Rep; 2005 May; 13(5):853-7. PubMed ID: 15809749
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis.
Hajitou A; Sounni NE; Devy L; Grignet-Debrus C; Lewalle JM; Li H; Deroanne CF; Lu H; Colige A; Nusgens BV; Frankenne F; Maron A; Yeh P; Perricaudet M; Chang Y; Soria C; Calberg-Bacq CM; Foidart JM; Noël A
Cancer Res; 2001 Apr; 61(8):3450-7. PubMed ID: 11309307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
